Comparison of the effectiveness of captopril and olmesartan in hypertensive patients
Abstract views: 149 / PDF downloads: 79
Keywords:Emergency department, hypertension, captopril, olmesartan
Purpose: Hypertensive conditions are situations that require immediate intervention in emergency services. Captopril is one of the most commonly used drugs in patients presenting to emergency departments with high blood pressure. In this study; we aimed to find an answer to the question of whether orally administered olmesartan could be an alternative to captopril in urgent hypertensive situations. Material and Method: In this study, blood pressure measurements were made after a 5-minute rest period in patients who presented to the emergency department of our hospital with the diagnosis of hypertension. Patients with a blood pressure of 180/100 mmHg and above and no signs of end-organ damage were followed up. Forty patients were given sublingual captopril 25 mg, and the other 40 patients were given 40 mg of olmesartan, and they were allowed to swallow the drug with some water. Afterward, the patients were followed for 3 hours (with blood pressure and pulse measurements), and their blood pressure was measured and recorded at five-minute intervals. Results: The mean age of the patients receiving captopril was 60.70±11.43 years, and the mean age of the patients receiving olmesartan was 57.02±13.86 years. Of the patients receiving captopril, 19 (57.5%) were male, 21 (52.5%) were female, 17 (42.5%) of the patients receiving olmesartan were male and 23 (57.5%) were female. In this study, patients treated with captopril and olmesartan were monitored for 3 hours and the differences between them in pulse and blood pressure measurements were evaluated. When the systolic blood pressures were compared, the difference at the tenth minute was significant, but the difference between the other minutes was not significant. Differences in diastolic blood pressure and heart rate were not significant. Conclusion: Oral administration of olmesartan in emergency hypertensive patients may be an alternative to captopril due to its effectiveness in reducing mortality and morbidity.
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46.
Guidelines Subcommittee of the WHO-International Society of Hypertension.Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D.Prevalance of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey,1988-1991.Hypertension 1995; 25: 303-4.
Onat A, Sansoy V, Soydan İ, Tokgözoğlu L, Adalet K.TEKHARF,oniki yıllık izleme deneyimine göre Türk erişkinlerinde kalp sağlığı.İstanbul Türkiye, 2003.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
Vaughan CJ, Delanty N. Hypertensive emergencies. The Lancet 2000; 356: 411-7.
Gökel Y, Satar S, Paydas S. A Comparison of the Effectiveness of Sublingual Losartan, Sublingual Captopril and Sublingual Nifedipine in Hypertensive Urgency. Tr. J. of Medical Sciences 1999; 29: 655-60.
Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Human Hypertens 2002; 16: 24–8.
Hasenfuss G. AT(1) blocker for post-infarct therapy. VALIANT Study Internist (Berl). 2004; 45: 946-8.
Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol. 1999: 15; 83: 477-81.
Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875-86.
Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004; 148: 122-8.
Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997; 10: 705-13.
Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-9.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.